• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

AJMC® in the Press, September 28, 2018


Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

The Philadelphia Tribunes article on ChenMed highlighted a study published in the September issue of The American Journal of Managed Care® (AJMC®). The study, “High-Touch Care Leads to Better Outcomes and Lower Costs in a Senior Population,” evaluated the impact of a high-touch primary care model among a Medicare Advantage population in comparison with a standard practice—based model and found that the high-touch model improved healthcare utilization and reduced healthcare costs.

An article from Seeking Alpha mentioned the AJMC® published study “A Payer—Provider Partnership for Integrated Care of Patients Receiving Dialysis.” The study concluded that promising trends were observed among members participating in a payer—provider care partnership with respect to both clinical and economic outcomes.

The AJMC® article “Review Finds Mixed Results for APMs and New Care Delivery Models in Cancer” was included in OBR Oncology’s Monday newsfeed. The article covered a review that found limited evidence available to evaluate the efficacy of alternative payment and care models in cancer care.

The National Pharmaceutical Council (NPC)’s Monday CER Daily Newsfeed mentioned an article from AJMC®’s The Center for Biosimilars®. The article, “UK Health System Wins the Right to Treat AMD With Bevacizumab,” reported that the United Kingdom had ruled in favor of the National Health Service, allowing the health system to provide intravitreal injections of the anti—vascular endothelial growth factor agent bevacizumab to patients with age-related macular degeneration.

NPC's Thursday CER Daily Newsfeed also included an article from The Center for Biosimilars®. “With Payers Under Pressure, Biosimilars Must Demonstrate Their Value” covered a session from the SMi 9th annual conference on Biosimilars and Biobetters that discussed payers facing heightened pressure to lower costs in order to afford innovative therapies.

Related Videos
Dr Mrinal Gounder
Related Content
© 2023 MJH Life Sciences
All rights reserved.